

QUARTERLY FINANCIAL INFORMATION AT 31 DECEMBER 2008
**2008 REVENUES: TARGET COMFORTABLY MET
2008 MARGIN: OUTLOOK CONFIRMED**

Paris, 11 February 2009 - Cegedim, the world leader in Customer Relationship Management (CRM) for the pharmaceutical industry, generated consolidated revenues of €849 million in 2008, up 16.6% like-for-like* compared with 2007 and a 12.7% rise on a reported basis.

Revenues were in every respect consistent with the guidance that Cegedim Group gave last April despite negative currency effects, confirming the positive impact of the Dendrite acquisition and the financial crisis' marginal impact on Group activities.

2008 consolidated revenues (not audited)

IFRS (€ THOUSANDS)	2008	2007	% change as reported	2008 like-for-like ^(*)	2007 like-for-like ^(*)	Change like-for-like ^(*)
CRM and strategic data	492,646	460,069	+7.1%	503,365	451,281	+11.5%
Healthcare professionals	250,284	191,356	+30.8%	259,504	191,356	+35.6%
Insurances and services	105,744	101,569	+4.1%	101,654	98,574	+3.1%
Total revenues	848,674	752,994	+12.7%	864,523	741,211	+16.6%

Consolidated revenues by quarter (not audited)

IFRS (€ THOUSANDS)	Q1 08	Q2 08	Q3 08	Q4 08	Q1 07	Q2 07	Q3 07	Q4 07
CRM and strategic data	115,764	124,638	109,837	142,405	67,290	118,888	126,660	147,232
Healthcare professionals	48,684	76,401	54,710	70,490	44,053	49,947	43,702	53,653
Insurances and services	25,379	27,214	24,353	28,799	24,707	28,255	21,346	27,261
Total revenues	189,827	228,253	188,900	241,694	136,050	197,090	191,708	228,146

() at constant exchange rates. As a reminder, like-for-like growth is not restated for Dendrite's activities, which were acquired in May 2007 and whose impact on the "CRM and strategic data" sector is no longer distinguishable due to intervening mergers.*

Fourth-quarter revenues came to €242 million, up 8.8% like for like* compared with Q4 2007 and 6.0% on a reported basis. Cegedim managed to generate this substantial increase despite a very negative currency impact and the expected downturn in business at its principal US client. As the company has said, the fourth quarter is traditionally the Group's busiest.

CRM and strategic data

2008 revenues came to €493 million, an 11.5% like-for-like* increase and a 7.1% increase on a reported basis, reflecting the following factors:

- Performance in market research for the healthcare industry was excellent, early demand for Dendrite products like Mobile Intelligence is strong in Europe, and the Group strengthened its global presence.
- The currency impact erased 2.6% of *CRM and strategic data* revenues, due notably to the euro's appreciation against the dollar and sterling.

Fourth-quarter revenues came to €142 million. They were unchanged like for like* compared with Q4 2007 and fell 3.2% on a reported basis. Restated by the expected downturn in business at the Group's principal US client, revenues rose by around 5%, confirming Dendrite's successful integration.

Healthcare professionals

2008 revenues came to €250 million, up 35.6% like for like* and 30.8% on a reported basis, reflecting the following factors:

- The pharmacist, physician and paramedic software business posted strong double-digit growth. The Group continued its European development, expanding particularly in the UK, Belgium, Spain and Italy.
- Pharmacist services businesses, like RNP (POS advertising), and Cegelease (financial leasing) also made strong contributions to the sector's growth.
- Exchange rates had a negative impact of 4.1% on *Healthcare professionals* revenues, due notably to the euro's appreciation against sterling.

Q4 revenues came to €70 million, up 36.5% like for like* compared with Q4 2007 and 31.4% on a reported basis. This growth confirms the healthcare sector's traditionally defensive aspect.

Insurance and services

2008 revenues came to €106 million, up 3.1% like for like* and 4.1% on a reported basis, reflecting the following factors:

- Growth of 9% in the second half following a 1% contraction in the first half. This recovery underlines the soundness of the investments in the sector and acquisitions made in computerization for insurers and mutual health insurers, as well as in data flow management.
- The currency impact on *Insurance and services* turnover was not significant because the vast majority of its sales are generated in France.

Q4 revenues came to €29 million, up 4.1% like for like* compared with Q4 2007 and 5.7% on a reported basis. This revenue growth is in line with the business' historical growth rate.

Important events and transactions in Q4 2008

As part of integrating Dendrite, the Group sold part of its activities in the US in the fourth quarter. Pursuant to the terms of the agreement, the details of the transaction are confidential.

2008-2009 outlook

As stated in April and September, the Group is maintaining its 2008 target for an operating margin in line with 2007. For the avoidance of doubt, it excludes non-recurring charges (IFRS) and restructuring and integration costs.

Cegedim is aiming for a small increase in 2009 revenues. Furthermore, all of the policies implemented in 2008 are likely to help boost margins.

Strong sales growth at Cegelease combined with significant R&D efforts and a desire to prioritize free cash flow generation and the external growth financing have led the Group to consider not paying a dividend in respect of 2008.

Agenda

The Group's 2008 results will be announced 22 April 2009 after stock market closing. An analyst meeting will be held on 23 April 2009 at Cegedim's corporate office.

About Cegedim:

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies.

The world leader in pharmaceutical CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs more than 8,000 people in 80 countries and generated revenue of €849 million in 2008. To learn more, please visit our website: www.cegedim.com

Listed on NYSE Euronext Paris, compartment B – ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM

Media inquiries

Cegedim

Aude Balleydier
Sylvie Delangle
Media Relations
Tel: + 33 (0)1 49 09 68 81
sylvie.delangle@cegedim.fr

Presse & Papiers

Guillaume de Chamisso
Attaché de Presse
Tel: + 33 (0)1 77 35 60 99
guillaume.dechamisso@pressepapiers.fr

Investor relations

Cegedim

Jan Eryk Umiastowski
Tel: + 33 (0)1 49 09 33 36
investor.relations@cegedim.fr